DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 21775/S-007

SUPPLEMENT APPROVAL

Cubist Pharmaceuticals
Attention: Jeffrey P. Bourque
Director, Regulatory Affairs
65 Hayden Avenue
Lexington, MA 02421

Dear Mr. Bourque:

Please refer to your Supplemental New Drug Application (sNDA) dated October 14, 2011, received October 17, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Entereg (alvimopan) Capsules, 12 mg.

We acknowledge receipt of your amendment dated April 24, 2012. We also acknowledge your risk evaluation and mitigation strategy (REMS) assessment dated May 18, 2012, which was found to be complete on July 12, 2012.

This supplemental new drug application provides for proposed modifications to the approved REMS.

RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS

The REMS for Entereg (alvimopan) was originally approved on May 20, 2008, and a REMS modification was approved on February 5, 2009. The REMS consists of a communication plan, elements to assure safe use, implementation system, and a timetable for submission of assessments of the REMS. Your proposed modifications to the REMS consist of:

- Modifications resulting from Cubist Pharmaceuticals acquisition of Entereg (alvimopan) from Adolor Corporation on December 1, 2011
- New hospital registration form with addition of checkboxes
- Updates to the E.A.S.E. Program trademark and National Drug code (NDC)

Your proposed modified REMS, submitted on April 24, 2012, and appended to this letter, is approved.

The timetable for submission of assessments of the REMS will remain the same as that approved on May 20, 2008.

There are no changes to the REMS assessment plan described in our July 16, 2012, letter.

In addition to the assessments submitted according to the timetable included in the approved REMS, you must submit a REMS assessment and may propose a modification to the approved REMS when you submit a supplemental application for a new indication for use as described in section 505-1(g)(2)(A) of FDCA.

If the assessment instruments and methodology for your REMS assessments are not included in the REMS supporting document, or if you propose changes to the submitted assessment instruments or methodology, you should update the REMS supporting document to include specific assessment instrument and methodology information at least 90 days before the assessments will be conducted. Updates to the REMS supporting document may be included in a new document that references previous REMS supporting document submission(s) for unchanged portions. Alternatively, updates may be made by modifying the complete previous REMS supporting document, with all changes marked and highlighted. Prominently identify the submission containing the assessment instruments and methodology with the following wording in bold capital letters at the top of the first page of the submission:

NDA 21775 REMS CORRESPONDENCE
(insert concise description of content in bold capital letters, e.g.,
UPDATE TO REMS SUPPORTING DOCUMENT - ASSESSMENT METHODOLOGY)

If you currently distribute or plan to distribute an authorized generic product under this NDA, you must submit a complete proposed REMS that relates only to the authorized generic product. Submit a proposed REMS, REMS supporting document, and any required appended documents as a prior approval supplement. Approval of the proposed REMS is required before you may market your authorized generic product.

Prominently identify the submission containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

NDA 21775 REMS ASSESSMENT

NEW SUPPLEMENT FOR NDA 21775
PROPOSED REMS MODIFICATION
REMS ASSESSMENT

NEW SUPPLEMENT (NEW INDICATION FOR USE)
FOR NDA 21775
REMS ASSESSMENT
PROPOSED REMS MODIFICATION (if included)

If you do not submit electronically, please send 5 copies of REMS-related submissions.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Matthew Scherer, Regulatory Project Manager, at (301) 796-2307.

Sincerely,

{See appended electronic signature page}

Joyce Korvick, M.D., M.P.H.
Deputy Director for Safety
Division of Gastroenterology and Inborn Errors Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE:
REMS

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOYCE A KORVICK
09/25/2012